OncoPharm

The Landmarks in Oncology Pharmacy series returns with a review of 2 ondansetron studies from 1990, published simultaneously in NEJM.

Recapping (some) of the top stories from ASCO18 starting with breast cancer (TAILOR-Rx, PERSEPHONE, SANDPIPER, S0927); then NSCLC (11:35) with Keynote-42 & LOXO-292; then mylemoa (16:50) with a CAR-T update and a new dosing of carfilzomib; before ending (20:30) with CARMENA and PRODIGY-24's new mFOLFIRINOX data for adjuvant pancreatic cancer. Whew!

Previewing this week's ASCO annual meeting and the Plenary Sessions (briefly) and selected abstracts highlighting oncology pharmacy practice.

Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.

The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.

Cytarabine, the 'c' chemotherapy from the sea, is discussed.

Recent FDA updates are discussed including combined use of BRAF & MEK inhibitors, frontline daratumumab (10:20), and your next P & T monograph drug to review.

Dive into the fascinating journey of methotrexate, from its origins as an antifolate to a cornerstone in chemotherapy. Discover its mechanisms, dosing intricacies, and safety measures vital for treating acute lymphoblastic leukemia and other conditions. This exploration highlights how this once-simple drug has evolved into a crucial player in modern oncology, showcasing its lasting impact on patient care.

Recent FDA & #oncopharm updates are discussed, including irinotecan in sweat, fostamatinib's FDA-approval for ITP. Then, immunotherapy updates from AACR are reviewed (6:00). Finally (34:00 , osimertinib's updated approval for frontline use in mEGFR NSCLC.

You've heard of NSABP, but have you heard of adjuvant melphalan, 5-FU, & concurrent tamoxifen? Sometimes asking the right question yields answers we don't yet understand.